Comparison · NCT01644331-84a3e965
Tolvaptan vs Placebo: Worsening or Persistent Heart Failure or Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tolvaptan vs Placebo: Worsening or Persistent Heart Failure or Death. Trial comparisons, record NCT01644331-84a3e965. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01644331-84a3e965
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.419 | 0.337 | 0.505 | wilson | |
| Risk in group 2 | 0.469 | 0.384 | 0.555 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0501 | -0.169 | 0.0705 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.893 | 0.679 | 1.18 | log | |
| Odds ratio, group 1 over group 2 | 0.816 | 0.498 | 1.34 | log | |
| Number needed to treat, for one fewer participant with the outcome on Tolvaptan than on Placebo | 19.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tolvaptan | IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)~Tolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours) | 54 | 129 | OG000 |
| Group 2 | Placebo | IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)~Placebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours) | 60 | 128 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Worsening or Persistent Heart Failure or Death
- Description
- Number of patients with worsening heart failure or death
- Time frame
- 72 hrs
- Population
- baseline population
Source ClinicalTrials.gov
Trial
- Title
- Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
- NCT number
- NCT01644331
- Phases
- PHASE3
- Conditions
- Heart Failure, Dyspnea
- Interventions
- Tolvaptan, Placebo
- Lead sponsor
- Duke University
- Results first posted
- 2017-04-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01644331?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01644331-84a3e965